Hypothesis: Catheter-based renal sympathetic denervation should be the initial therapy for essential hypertension

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Interventional Cardiology

Background:

• Hypertension impacts 30-40% of adults globally, increasing risks for stroke, heart attack, heart failure, and kidney failure.
• Despite recognized importance, only 50% of US patients achieve blood pressure goals due to noncompliance, medication issues, and resistance.
• Renal sympathetic denervation is an established treatment for resistant hypertension, demonstrating safety, efficacy, and durability.

Purpose of the Study:

• To hypothesize that renal sympathetic denervation yields consistent results across the spectrum of hypertension severity.
• To propose testing this hypothesis in robust, randomized clinical trials.

Main Methods:

• Review of existing data on renal sympathetic denervation for resistant hypertension.
• Formulation of a hypothesis for broader application of the procedure.
• Proposal for future randomized controlled trials.

Main Results:

• Renal sympathetic denervation is safe, effective, and durable for resistant hypertension.
• The study hypothesizes similar efficacy across varying hypertension severities.

Conclusions:

• Renal sympathetic denervation may offer a viable treatment option beyond current resistant hypertension indications.
• Further research via large-scale randomized trials is crucial to validate the hypothesis and expand treatment guidelines.